Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting
For T2DM patients who remain uncontrolled on basal insulin, IDegLira was projected to be dominant and could offer better value compared to both basal-bolus therapy and GLP-1RA added to basal insulin in the Chinese setting.
Authors
- Junling Weng
- Yingyao Chen (ORCID: https://orcid.org/0000-0002-3470-0748)
- Dunming Xiao
Institutions
- Fudan University (CN)
- National Health and Family Planning Commission (CN)
Publication Details
- Journal
- Diabetology & Metabolic Syndrome
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1186/s13098-025-01722-8
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29